Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.

ABSTRACT:

Background

Characteristics of patients using newer 2^nd and 3^rd line antidiabetic drugs in a real-world setting are poorly understood. We described the characteristics of new users of sodium-glucose co-transporter-2 inhibitors (SGLT-2i), dipeptidyl peptidase-4 inhibitors (DPP-4i), and glucagon-like peptide-1 receptor agonists (GLP-1 RA) in Canada and the United Kingdom (UK) between 2016 and 2018.

Methods

We conducted a multi-database cohort study using administrative health databases from 7 Canadian provinces and the UK Clinical Practice Research Datalink. We assembled a base cohort of antidiabetic drug users between 2006 and 2018, from which we constructed 3 cohorts of new users of SGLT-2i, DPP-4i, and GLP-1 RA between 2016 and 2018.

Results

Our

SUBMITTER: Brunetti VC 

PROVIDER: S-EPMC9520836 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature